| First Author | Ghazi PC | Year | 2024 |
| Journal | Elife | Volume | 13 |
| PubMed ID | 39213022 | Mgi Jnum | J:361505 |
| Mgi Id | MGI:7859081 | Doi | 10.7554/eLife.96992 |
| Citation | Ghazi PC, et al. (2024) Inhibition of ULK1/2 and KRAS(G12C) controls tumor growth in preclinical models of lung cancer. Elife 13 |
| abstractText | Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent U.S. Food and Drug Administration approval of covalent inhibitors of KRAS(G12C) such as sotorasib or adagrasib, KRAS oncoproteins are important pharmacological targets in non-small cell lung cancer (NSCLC). However, not all KRAS(G12C)-driven NSCLCs respond to these inhibitors, and the emergence of drug resistance in those patients who do respond can be rapid and pleiotropic. Hence, based on a backbone of covalent inhibition of KRAS(G12C), efforts are underway to develop effective combination therapies. Here, we report that the inhibition of KRAS(G12C) signaling increases autophagy in KRAS(G12C)-expressing lung cancer cells. Moreover, the combination of DCC-3116, a selective ULK1/2 inhibitor, plus sotorasib displays cooperative/synergistic suppression of human KRAS(G12C)-driven lung cancer cell proliferation in vitro and superior tumor control in vivo. Additionally, in genetically engineered mouse models of KRAS(G12C)-driven NSCLC, inhibition of either KRAS(G12C) or ULK1/2 decreases tumor burden and increases mouse survival. Consequently, these data suggest that ULK1/2-mediated autophagy is a pharmacologically actionable cytoprotective stress response to inhibition of KRAS(G12C) in lung cancer. |
